Bioequivalence of azathioprine products

Reviews in Gastroenterological Disorders

Volumn 3, Issue 4, 2003, Pages 219-223

  Baker, Daniel E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

6 Mercaptopurine; Azathioprine; Bioavailability; Bioequivance; Pharmacogenetics; Thiopurine methytransferase (TPMT)

Indexed keywords

AZATHIOPRINE; AZATHIOPRINE DERIVATIVE; CARBAMAZEPINE; CYCLOSPORIN; DIGOXIN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; LEVOTHYROXINE; MERCAPTOPURINE; PHENYTOIN; STEROID; TACROLIMUS; THEOPHYLLINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; WARFARIN;

BIOEQUIVALENCE; BONE MARROW TOXICITY; CLINICAL TRIAL; CROHN DISEASE; DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENOMICS; POPULATION RESEARCH; REMISSION; REVIEW; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0347589254     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: a National Kidney Foundation White Paper. Am J Kidney Dis. 1999;33:389-397.
2. Vasquez EM, Min DI. Transplant pharmacists' opinions on generic product selection of critical-dose drugs. Am J Health-Syst Pharm. 1999;56:615-621.
3. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol. 2001;15:405-417.
4. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24:330-350.
5. Reiffel JA. Issues in the use of generic antiarrhythmic drugs. Curr Opinion Cardiol. 2001; 16:23-29.
6. Yacobi A, Masson E, Moros D, et al. Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. J Clin Pharmacol. 2000;40:826-835.
7. Burns M. Management of narrow therapeutic index drugs. J Thromb Thrombolysis. 1999; 7:137-143.
8. Benet LZ. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplantation Proc. 1999;31:1642-1644.
9. Levy G. What are narrow therapeutic index drugs? Clin Pharmacol Ther. 1998;63:501-505.
10. Nightingale SL. Therapeutic equivalence of generic drugs: letter to health professionals. Center for Drug Evaluation. Food and Drug Administration web site. February 4, 1998. Available at: http://www.fda.gov/cder/news/nightgenlett.htm. Accessed June 4, 2003.
11. Williams RL. Therapeutic equivalence of generic drugs: response to National Association of Boards of Pharmacy [letter]. Center for Drug Evaluation and Research. Food and Drug Administration web site. April 16, 1997. Available at: http://www.fda.gov/cder/news/ntiletter.htm. Accessed June 4, 2003.
12. FDA Advisory Committee for Pharmaceutical Sciences' Briefing Document: Levothyroxine Bioequivalence. Abbott Park, Ill: Abbott Laboratories; March 2003.
13. Olyaei AJ, deMattos AM, Bennett WM. The impact of generic drugs on the cost of transplantation medical care. Transplantation Proc. 1999;31(suppl 3A):31S-34S.
14. Barr WH. Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets. Transplantation Proc. 1999; 31(suppl 3A):25S-30S.
15. Food and Drug Administration Center for Drug Evaluation and Research. Approved drug products with therapeutic equivalence evaluations. 23rd Edition. May 2003. Available at: http://www.fda.gov/cder/ob/default.htm. Accessed July 10, 2003.
16. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharmaceutical Res. 2001; 18:1645-1650.
17. Dighe SV. A review of the safety of generic drugs. Transplantation Proceedings. 1999; 31(suppl 3A):23S-24S.
18. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: average, population, and individual approaches to establishing bioequivalence. August 1999. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/3657gdl.pdf. Accessed June 4, 2003.
19. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14:1009-1014.
20. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochemistry. 2001;34:9-16.
21. Arnott IDR, Watts D, Satsangi J. Azathioprine and anti-TNFalpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacological Res. 2003;47:1-10.
22. Corominas H, Domenech M, Gonzalez D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol. 2000;95:2313-2317.
23. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monitoring. 1996;18:328-334.
24. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics. 2002; 3:89-98.
25. Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J. 2001;1:254-261.
26. Siva C, Yokoyama WM, McLeod HL. Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. Rheumatology. 2002;41:1273-1279.
27. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
28. Schwartz JB. Pharmacogenetics: has it reached the clinic? J Gend Specif Med. 2002 Mar-Apr;5:13-18.
29. Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev. 2000;19:293-312.
30. Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet. 2000;45:299-302.
31. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;341:436.
32. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B-27-associated spondylarthritis. Arthritis Rheum. 1997;40:1896-1898.
33. Schutz E, Gummert J, Mohr FW, et al. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit. 1996;18:228-233.
34. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Phamacol Ther. 1989;46:149-154.
35. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999;39:19-52.
36. Lennard L, Van Loon JA, Lilleyman SJ, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987;41:18-25.
37. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193-197.
38. Oscarson M. Pharmacogenetics of drug metabolizing enzymes: importance for personalized medicine. Clin Chem Lab Med. 2003; 41:573-580.
39. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990; 336:225-229.
40. Chocair PR, Duley JA, Sabbaga E, et al. Fast and slow methylators: do racial differences influence risk of allograft rejection? Quarterly J Med. 1993;86:359-363.